# A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003)

> **NCT02059161** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 508 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** MK-1293
- **DRUG:** Lantus™
- **DRUG:** Prandial Insulin

## Key facts

- **NCT ID:** NCT02059161
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-17
- **Primary completion:** 2015-05-04
- **Final completion:** 2015-11-12
- **Target enrollment:** 508 (ACTUAL)
- **Last updated:** 2018-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02059161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02059161, "A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02059161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*